Durvalumab
From IDWiki
Revision as of 19:43, 7 February 2024 by Aidan (talk | contribs) (Created page with "* Human IgG1k monoclonal antibody that blocks PD-L1 from interacting PD-1 and CD-80 * Indicated for urothelial carcinoma, small cell lung cancer, non-small cell lung cancer * Adverse effects include ** Cardiac: hypertension (6%), myocarditis (rare) ** Dermatologic: rash with pruritus (22%) ** Gastrointestinal: abdominal pain (10%), anorexia (14%), constipation (12%), diarrhea (18%), colitis (2%), nausea/vomiting (14%) ** General: edema (8%), fatigue (...")
- Human IgG1k monoclonal antibody that blocks PD-L1 from interacting PD-1 and CD-80
- Indicated for urothelial carcinoma, small cell lung cancer, non-small cell lung cancer
- Adverse effects include
- Cardiac: hypertension (6%), myocarditis (rare)
- Dermatologic: rash with pruritus (22%)
- Gastrointestinal: abdominal pain (10%), anorexia (14%), constipation (12%), diarrhea (18%), colitis (2%), nausea/vomiting (14%)
- General: edema (8%), fatigue (24%)
- Hematologic: immune-mediated thrombocytopenic purpura (rare)
- Hepatobiliary: elevated liver tests (6%), hepatitis (2%), pancreatitis (rare)
- Hypersensitivity: infusion reactions (2%)
- Infection (26%): UTI and pneumonia most commonly
- Metabolic: adrenal insufficiency (rare), diabetes mellitus (rare), hyperthyroidism (8%), hypophysitis (rare), hypothyroidism (12%), thyroiditis (2%)
- MSK: pain (12%)
- CNS: aseptic meningitis or encephalitis (rare), headache (11%), insomnia (10%)
- Ophthalmic: uveitis (rare)
- Renal: increased creatinine (5%)
- Respiratory: cough or dyspnea (40%), severe cough or dyspnea (1%), dysphonia (4%), pneumonitis (3%, but up to 34% in NSCLC)
